Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Default

Display 45 Products per page

Market Spotlight: Uterine Fibroids

$1,318.00

This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, Recent Events and Analyst Opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

$1,318.00

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Market Spotlight: Systemic Hypertension

$1,318.00

This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Market Spotlight: Tumor Lysis Syndrome (TLS)

$1,318.00

Tumor lysis syndrome (TLS) comprises a group of metabolic disturbances that result from either chemotherapy or spontaneously induced tumor cell death. The release of intracellular components, including nucleic acids, electrolytes, and proteins, into the systemic circulation is triggered by tumor cytotoxicity. This may result in the development of metabolic abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinically, this can lead to effects on multiple organs such as cardiac arrhythmias, seizures, and acute kidney injury.
May 5, 2022
Find out more
Market Spotlight: Mesothelioma

$1,318.00

This Market Spotlight report covers the mesothelioma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Disease Analysis: Human Papillomavirus (HPV) Vaccines
Read More
HPV is a member of the papillomavirus family, which are known for causing warts. Over 200 different types have been identified so far, and while most HPV infections are not harmful, persistent infection with certain HPV strains can cause warts and anogenital lesions, which if untreated may become cancers. HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection. Other cancers related to HPV include cancers of the vulva, vagina, penis, or anus. Only about 14 HPV strains are considered high risk for causing cervical cancer, and of these the two most common types, HPV 16 and 18, are responsible for causing around 70% of all cervical cancers globally.
May 5, 2022
Find out more
Market Spotlight: Waldenström Macroglobulinemia (WM)

$1,318.00

This Market Spotlight report covers the Waldenström Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, regulatory events, recent events and analyst opinion, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments.
May 4, 2022
Find out more
Disease Analysis: Seasonal Influenza Vaccines
Read More
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates.
April 29, 2022
Find out more
Market Spotlight: Eating Disorders

$1,318.00

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
April 28, 2022
Find out more
Market Spotlight: Gastrointestinal Stromal Tumor (GIST)

$1,318.00

This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.
April 28, 2022
Find out more
Market Spotlight: Lysosomal Storage Disorders

$1,318.00

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.
April 28, 2022
Find out more
Disease Analysis Atopic Dermatitis
Read More
Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. The condition usually begins during early infancy and childhood, but can persist into, or start during, adulthood.
April 22, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Market Spotlight: Sarcoma

$1,318.00

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Market Spotlight: Neuroendocrine tumors (NET)

$1,318.00

This Market Spotlight report covers the Neuroendocrine Tumors (NETs) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence and prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Market Spotlight: Biliary Tract Cancer

$1,318.00

This Market Spotlight report covers the Biliary Tract Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Market Spotlight: Benign Prostatic Hyperplasia (BPH)

$1,318.00

This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)
Read More
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which originates in the lymphatic system when B lymphocytes become enlarged and proliferate uncontrollably to form a tumor mass. DLBCL can arise de novo or as a progression or transformation from more indolent disease such as chronic lymphocytic leukemia (in which case it is also known as Richter’s transformation) or follicular lymphoma (FL).
April 21, 2022
Find out more
Market Spotlight: Glioblastoma (GBM)

$1,318.00

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Amyloidosis

$1,318.00

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Zika virus

$1,318.00

This Market Spotlight report covers the Zika Virus market, comprising key pipeline therapies, clinical trials, probability of success, and epidemiology.
April 14, 2022
Find out more
Market Spotlight: Dry Eye Disease

$1,318.00

This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

$1,318.00

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Disease Analysis: Dengue Vaccines
Read More
Dengue virus is a member of the Flaviviridae family, which are also known for causing other diseases including yellow fever, West Nile virus, and tick-borne encephalitis. There are four serologically distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4), meaning that recovery from infection provides immunity against a specific serotype, but there is little to no cross-immunity towards other serotypes. As a result, a person can be infected multiple times in their lifetime, with subsequent infections being more likely to be severe due to a phenomenon called antibody-dependent enhancement of disease.
April 12, 2022
Find out more
Disease Analysis: Depression
Read More
While it is not uncommon to experience feelings of sadness occasionally, in most people these emotions are usually fleeting and pass after a few days. When this manifests in a depressive disorder, a patient’s symptoms interfere with daily life and normal functioning. Depression is the leading cause of disability globally and can cause a multitude of symptoms, many of which are associated with impairment and, ultimately, decreased productivity
April 8, 2022
Find out more
Market Spotlight: Thyroid Cancer

$1,318.00

This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Irritable Bowel Syndrome (IBS)

$1,318.00

This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Acne

$1,318.00

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Hereditary Angioedema

$1,318.00

This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Celiac Disease

$1,318.00

Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
April 7, 2022
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Polycystic Ovary Syndrome (PCOS)

$1,318.00

This Market Spotlight report covers the Polycystic Ovary Syndrome (PCOS) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
April 7, 2022
Find out more
Market Spotlight: Atrial Fibrillation

$1,318.00

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Disease Analysis: Psoriatic Arthritis
Read More
Psoriatic arthritis is grouped with spondyloarthritis and is characterized by inflammation in the spine (spondylitis) and/or joints (arthritis). It is often preceded by a diagnosis of psoriasis by about 10 years. The disease may be characterized by joint pain, swelling, or morning stiffness, and about 80–90% of psoriatic arthritis patients experience nail lesions, which include pitting (dents) and onycholysis (detachment). Around 30% of individuals with psoriasis develop psoriatic arthritis.
March 30, 2022
Find out more
Disease Analysis: Schizophrenia
Read More
The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.
March 30, 2022
Find out more
Disease Analysis: Rheumatoid Arthritis
Read More
The rheumatoid arthritis (RA) market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars, and encourage uptake.
March 24, 2022
Find out more
Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)
Read More
Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as due to Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues.
March 23, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

$599.00

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

$599.00

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Drug Delivery: Injection Devices

$4,750.00

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn.
March 15, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *